Keytruda post-surgery could halt return of distant tumours in rare skin cancer
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
List view / Grid view
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
The innovative approach facilitates QSRR-assisted chromatographic development for N-nitrosamine analysis in pharmaceutical products.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
EMA advisors at the CHMP backed the combination treatment and also recommended Bayer’s menopause drug Lynkuet, putting both on the path to being licensed.
Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs.
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.